SARS-CoV-2 vaccination in the first year after allogeneic hematopoietic cell transplant: a prospective, multicentre, observational study

BACKGROUND: The optimal timing for SARS-CoV-2 vaccines within the first year after allogeneic hematopoietic cell transplant (HCT) is poorly understood. METHODS: We conducted a prospective, multicentre, observational study of allogeneic HCT recipients who initiated SARS-CoV-2 vaccinations within 12 m...

Descripción completa

Detalles Bibliográficos
Autores principales: Hill, Joshua A., Martens, Michael J., Young, Jo-Anne H., Bhavsar, Kavita, Kou, Jianqun, Chen, Min, Lee, Lik Wee, Baluch, Aliyah, Dhodapkar, Madhav V., Nakamura, Ryotaro, Peyton, Kristin, Shahid, Zainab, Armistead, Paul, Westervelt, Peter, McCarty, John, McGuirk, Joseph, Hamadani, Mehdi, DeWolf, Susan, Hosszu, Kinga, Sharon, Elad, Spahn, Ashley, Toor, Amir A., Waldvogel, Stephanie, Greenberger, Lee M., Auletta, Jeffery J., Horowitz, Mary M., Riches, Marcie L., Perales, Miguel-Angel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10133891/
https://www.ncbi.nlm.nih.gov/pubmed/37128256
http://dx.doi.org/10.1016/j.eclinm.2023.101983

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10133891/
https://www.ncbi.nlm.nih.gov/pubmed/37128256
http://dx.doi.org/10.1016/j.eclinm.2023.101983

Ejemplares similares